Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline Review, H2 2012

Published: December 2012
No. of Pages: 134
   

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ''Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2012'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease). Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Coronary Artery Disease (CAD) (Ischemic Heart Disease).
- A review of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) 11
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics under Development by Companies 13
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Discovery and Pre-Clinical Stage Products 22
Comparative Analysis 22
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics – Products under Development by Companies 23
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics – Products under Investigation by Universities/Institutes 25
Companies Involved in Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Development 27
Bristol-Myers Squibb Company 27
Isis Pharmaceuticals, Inc. 28
Daiichi Sankyo Company, Ltd 29
Merck & Co., Inc. 30
CardioVascular BioTherapeutics, Inc. 31
Reliance Life Sciences Pvt. Ltd. 32
Novartis AG 33
Momenta Pharmaceuticals, Inc. 34
BioInvent International AB 35
Resverlogix Corp. 36
Evolva SA 37
AngioDesign 38
Regado Biosciences. 39
Phage Biotechnology Corporation 40
Medistem, Inc. 41
Viromed Co., Ltd. 42
Lee''s Pharmaceutical Holdings Limited 43
Pfenex Inc. 44
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Combination Products 46
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 52
anacetrapib - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
BI-204 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
LXR Modulators - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
CVBT-141H - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
adomiparin - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
CVBT-141A - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
anivamersen + pegnivacogin - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
EV-077 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
RVX-208 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
cangrelor - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
FGF-1 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
VM-202 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
icatibant - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
testosterone - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
prasugrel hydrochloride - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Telmisartan + Bisoprolol - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
LCQ-908 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
prasugrel hydrochloride - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
FGF-1141 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
BQ-123 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
icosapent ethyl - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
pioglitazone hydrochloride - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
pioglitazone hydrochloride - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
amiloride - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Endocardial Adenovirus VEGF-D Gene Therapy - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
MZ-004 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Neo-Vessel Replacement - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
paclitaxel - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
ISIS-CRPRx - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Custodiol-N - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
ACP-501 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
rosiglitazone maleate - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Angiostem Derivatives - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
pentoxifylline - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
MultiGeneGraft - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
ZK-001 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Abciximab Biosimilar - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Abciximab Biosimilar - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
NaCl + Hydroxyethyl Starch - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
umirolimus - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
CREKA-bivalirudin - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Autologous Intracoronary Stem Cells - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics – Drug Profile Updates 105
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics – Discontinued Products 118
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics - Dormant Products 119
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Product Development Milestones 123
Featured News & Press Releases 123
Nov 13, 2012: Bayer Announces Initiation Of COMPASS Phase III Study Of Xarelto For Secondary Prevention Of Myocardial Infarction And Death In Patients With Coronary Or Peripheral Artery Disease 123
Oct 23, 2012: Daiichi Sankyo And Eli Lilly Announce Results From New Retrospective Studies In Acute Coronary Syndromes-Percutaneous Coronary Intervention Patients Treated With Effient 124
Sep 26, 2012: Resverlogix Completes Enrollment In Phase IIb Trial Of RVX-208 In Patients With Coronary Artery Disease 125
Aug 26, 2012: Merck Provides Update On Anacetrapib Development Program 126
Jul 02, 2012: The Medicines Company Expects Cangrelor Phase III Trial Enrollment Completion In 2012 127
Jun 29, 2012: BioInvent Focuses Resources On BI-204 And New Cancer Projects 128
Mar 30, 2012: AlphaCore Pharma Initiates Phase I Study Of ACP-501 In Patients With Coronary Artery Disease 128
Mar 02, 2012: BioInvent Completes Recruitment Of Patients In Phase II Study With BI-204 129
Dec 15, 2011: CHMP Adopts Positive Opinion Recommending Granting Of Marketing Authorization For Corlentor 129
Nov 16, 2011: New Analysis Of Data Presented At AHA Shows Effects Of Effient On Cardiovascular Events In STEMI Patients 130
Appendix 133
Methodology 133
Coverage 133
Secondary Research 133
Primary Research 133
Expert Panel Validation 133
Contact Us 134
Disclaimer 134

List of Tables
Number of Products Under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2012 11
Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Development by Companies, H2 2012 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2012 17
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 18
Comparative Analysis by Late Stage Development, H2 2012 19
Comparative Analysis by Mid Clinical Stage Development, H2 2012 20
Comparative Analysis by Early Clinical Stage Development, H2 2012 21
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 22
Products under Development by Companies, H2 2012 23
Products under Development by Companies, H2 2012 (Contd..1) 24
Products under Investigation by Universities/Institutes, H2 2012 25
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 26
Bristol-Myers Squibb Company, H2 2012 27
Isis Pharmaceuticals, Inc., H2 2012 28
Daiichi Sankyo Company, Ltd, H2 2012 29
Merck & Co., Inc., H2 2012 30
CardioVascular BioTherapeutics, Inc., H2 2012 31
Reliance Life Sciences Pvt. Ltd., H2 2012 32
Novartis AG, H2 2012 33
Momenta Pharmaceuticals, Inc., H2 2012 34
BioInvent International AB, H2 2012 35
Resverlogix Corp., H2 2012 36
Evolva SA, H2 2012 37
AngioDesign, H2 2012 38
Regado Biosciences., H2 2012 39
Phage Biotechnology Corporation, H2 2012 40
Medistem, Inc., H2 2012 41
Viromed Co., Ltd., H2 2012 42
Lee''s Pharmaceutical Holdings Limited, H2 2012 43
Pfenex Inc., H2 2012 44
Assessment by Monotherapy Products, H2 2012 45
Assessment by Combination Products, H2 2012 46
Assessment by Stage and Route of Administration, H2 2012 48
Assessment by Stage and Molecule Type, H2 2012 51
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics – Drug Profile Updates 105
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics – Discontinued Products 118
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics – Dormant Products 119
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics – Dormant Products (Contd..1) 120
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics – Dormant Products (Contd..2) 121
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics – Dormant Products (Contd..3) 122

List of Figures
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2012 11
Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 16
Late Stage Products, H2 2012 19
Mid Clinical Stage Products, H2 2012 20
Early Clinical Stage Products, H2 2012 21
Discovery and Pre-Clinical Stage Products, H2 2012 22
Assessment by Monotherapy Products, H2 2012 45
Assessment by Combination Products, H2 2012 46
Assessment by Route of Administration, H2 2012 47
Assessment by Stage and Route of Administration, H2 2012 48
Assessment by Molecule Type, H2 2012 49
Assessment by Stage and Molecule Type, H2 2012 50

Published By: Global Markets Direct
Product Code: Global Markets Direct5157


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100